38 related articles for article (PubMed ID: 20716265)
1. The 1987 National Women's Hospital 'Unfortunate experiment'.
Overton GH
Aust N Z J Obstet Gynaecol; 2011 Apr; 51(2):184; author reply 185-6. PubMed ID: 21466525
[No Abstract] [Full Text] [Related]
2. Screening of Precancerous Lesions in Women with Human Papillomavirus (HPV) Infection by Molecular Typing and MicroRNA Analysis.
Varesano S; Pulliero A; Martorana E; Pizzino G; Raciti G; Coco S; Vellone VG; Izzotti A
J Pers Med; 2023 Mar; 13(3):. PubMed ID: 36983713
[TBL] [Abstract][Full Text] [Related]
3. miR-23b-3p, miR-124-3p and miR-218-5p Synergistic or Additive Effects on Cellular Processes That Modulate Cervical Cancer Progression? A Molecular Balance That Needs Attention.
Romero-López MJ; Jiménez-Wences H; Cruz-De la Rosa MI; Román-Fernández IV; Fernández-Tilapa G
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362337
[TBL] [Abstract][Full Text] [Related]
4. Cervical cancer prevention and control in women living with human immunodeficiency virus.
Castle PE; Einstein MH; Sahasrabuddhe VV
CA Cancer J Clin; 2021 Nov; 71(6):505-526. PubMed ID: 34499351
[TBL] [Abstract][Full Text] [Related]
5. Cotesting in Cervical Cancer Screening.
Malinowski DP; Broache M; Vaughan L; Andrews J; Gary D; Kaufman HW; Alagia DP; Chen Z; Onisko A; Austin RM
Am J Clin Pathol; 2021 Jan; 155(1):150-154. PubMed ID: 33270087
[No Abstract] [Full Text] [Related]
6. Are CIN3 risk or CIN3+ risk measures reliable surrogates for invasive cervical cancer risk?
Austin RM; Onisko A; Zhao C
J Am Soc Cytopathol; 2020; 9(6):602-606. PubMed ID: 32839150
[TBL] [Abstract][Full Text] [Related]
7. Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature.
Kalliala I; Athanasiou A; Veroniki AA; Salanti G; Efthimiou O; Raftis N; Bowden S; Paraskevaidi M; Aro K; Arbyn M; Bennett P; Nieminen P; Paraskevaidis E; Kyrgiou M
Ann Oncol; 2020 Feb; 31(2):213-227. PubMed ID: 31959338
[TBL] [Abstract][Full Text] [Related]
8. The potential of RNA as a target for national screening of pre-cancer.
Karlsen F; Muturi M; Muyabwa C; Roseng LE; Bigabwa S; Chihongola B; Muchiri L
J Public Health Afr; 2018 Dec; 9(3):866. PubMed ID: 30854179
[TBL] [Abstract][Full Text] [Related]
9. MicroRNAs as markers of progression in cervical cancer: a systematic review.
Pardini B; De Maria D; Francavilla A; Di Gaetano C; Ronco G; Naccarati A
BMC Cancer; 2018 Jun; 18(1):696. PubMed ID: 29945565
[TBL] [Abstract][Full Text] [Related]
10. Low Risk of Cervical Cancer/Precancer Among Most Women Under Surveillance Postcolposcopy.
Demarco M; Cheung LC; Kinney WK; Wentzensen N; Lorey TS; Fetterman B; Poitras NE; Befano B; Castle PE; Schiffman M
J Low Genit Tract Dis; 2018 Apr; 22(2):97-103. PubMed ID: 29570564
[TBL] [Abstract][Full Text] [Related]
11. Role of quantitative p16
Vasiljević N; Carter PD; Reuter C; Warman R; Brentnall AR; Carton JR; Cuzick J; Lorincz AT
Int J Cancer; 2017 Aug; 141(4):829-836. PubMed ID: 28509346
[TBL] [Abstract][Full Text] [Related]
12. Paul and Brookes Respond.
Paul C; Brookes B
Am J Public Health; 2016 Jul; 106(7):1209-10. PubMed ID: 27285259
[No Abstract] [Full Text] [Related]
13. Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies.
Vici P; Pizzuti L; Mariani L; Zampa G; Santini D; Di Lauro L; Gamucci T; Natoli C; Marchetti P; Barba M; Maugeri-Saccà M; Sergi D; Tomao F; Vizza E; Di Filippo S; Paolini F; Curzio G; Corrado G; Michelotti A; Sanguineti G; Giordano A; De Maria R; Venuti A
Expert Rev Vaccines; 2016 Oct; 15(10):1327-36. PubMed ID: 27063030
[TBL] [Abstract][Full Text] [Related]
14. The Rationalization of Unethical Research: Revisionist Accounts of the Tuskegee Syphilis Study and the New Zealand "Unfortunate Experiment".
Paul C; Brookes B
Am J Public Health; 2015 Oct; 105(10):e12-9. PubMed ID: 26270295
[TBL] [Abstract][Full Text] [Related]
15. Correcting Error in Academic Publishing: An Ethical Responsibility.
Bunkle P
J Bioeth Inq; 2015 Dec; 12(4):665-73. PubMed ID: 26173775
[TBL] [Abstract][Full Text] [Related]
16. Prediction of spontaneous regression of cervical intraepithelial neoplasia lesions grades 2 and 3 by proteomic analysis.
Uleberg KE; Ovestad IT; Munk AC; Brede C; van Diermen B; Gudlaugsson E; Janssen EA; Hjelle A; Baak JP
Int J Proteomics; 2014; 2014():129064. PubMed ID: 25018881
[TBL] [Abstract][Full Text] [Related]
17. [Precancerous lesions of the uterine cervix: morphology and molecular pathology].
Horn LC; Klostermann K
Pathologe; 2011 Nov; 32 Suppl 2():242-54. PubMed ID: 21909794
[TBL] [Abstract][Full Text] [Related]
18. Discrimination of grade 2 and 3 cervical intraepithelial neoplasia by means of analysis of water soluble proteins recovered from cervical biopsies.
Uleberg KE; Munk AC; Brede C; Gudlaugsson E; van Diermen B; Skaland I; Malpica A; Janssen EA; Hjelle A; Baak JP
Proteome Sci; 2011 Jun; 9():36. PubMed ID: 21711556
[TBL] [Abstract][Full Text] [Related]
19. Consequences in women of participating in a study of the natural history of cervical intraepithelial neoplasia 3.
McCredie MR; Paul C; Sharples KJ; Baranyai J; Medley G; Skegg DC; Jones RW
Aust N Z J Obstet Gynaecol; 2010 Aug; 50(4):363-70. PubMed ID: 20716265
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
